Management of Menorrhagia

Diagnostic Approach

• The American College of Radiology recommends evaluating for iron deficiency anemia, as menorrhagia is the most common cause of iron deficiency in women of reproductive age, affecting 20-25% of this population 1, 2
• The American College of Radiology suggests searching for uterine pathology, such as fibroids, polyps, or adenomyosis, using imaging techniques like ultrasound or MRI 3
• It is essential to exclude coagulation disorders, particularly in women with severe thrombocytopenia 4

Treatment

• The American College of Obstetricians and Gynecologists recommends the levonorgestrel-releasing intrauterine system (LNG-IUS) as the most effective treatment for menorrhagia, reducing menstrual bleeding and improving quality of life 4
• The Centers for Disease Control and Prevention suggest that approximately 50% of LNG-IUS users develop amenorrhea or oligomenorrhea after 2 years of use 5, 6
• The American College of Obstetricians and Gynecologists recommends oral contraceptives as an alternative effective treatment, regularizing the cycle and reducing bleeding 4
• The use of progestins, such as norethindrone, is useful, particularly in women with severe thrombocytopenia, but should not be used for more than 6 months due to the risk of meningiomas 4

Anemia Treatment

• The American Gastroenterological Association recommends supplementing with iron, such as ferrous sulfate 200 mg three times a day, to correct anemia and replenish iron stores 1, 2
• The use of ascorbic acid can improve iron absorption and should be considered in cases of insufficient response 1, 2
• Treatment should be continued for three months after correction of anemia to replenish iron stores 1, 2

Surgical Options

• The American College of Radiology suggests that uterine artery embolization (UAE) is an alternative to surgery, with a clinical success rate of 81-100% 3
• The American College of Obstetricians and Gynecologists recommends considering UAE for women with menorrhagia, with improvement in symptoms in 83% of women at 3 months 3
• However, there is a risk of recurrence of symptoms in 20-25% of women at 5-7 years 3, 4

Follow-up

• The American Gastroenterological Association recommends monitoring hemoglobin and erythrocyte indices every 3 months for 1 year, then annually 1, 2
• Re-evaluation is necessary at 3-6 months after treatment to assess efficacy 3
• Further investigation is only necessary if hemoglobin and mean corpuscular volume (MCV) cannot be maintained within normal ranges 1, 2

First-Line Treatment for Menorrhagia

Primary Treatment Options

• The American College of Radiology suggests that combined oral contraceptive pills are effective for regularizing cycles and reducing bleeding, and are a suitable alternative when contraception is also desired 7

Alternative First-Line Medical Therapies

• Tranexamic acid, a non-hormonal option, is particularly effective in women with bleeding disorders or coagulopathies, and reduces menstrual blood loss by 34-59% over 2-3 cycles, according to the American College of Radiology 7

Special Populations

• The Centers for Disease Control and Prevention recommends that in women with severe thrombocytopenia, progestins may be useful but avoid DMPA due to irregular bleeding and 11-13 week irreversibility 8

Management of Menorrhagia with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

Efficacy and Recommendations

• The Centers for Disease Control and Prevention (CDC) recommends NSAIDs, such as mefenamic acid 500mg three times a day, as a treatment option for menorrhagia, particularly for short-term use (5-7 days) during bleeding episodes, with an efficacy of 20-35% reduction in menstrual blood loss 9
• The CDC also suggests that NSAIDs are suitable for women with irregular light bleeding or spotting while using injectable contraception, and for those who wish to avoid hormonal treatment, with mefenamic acid being the most frequently studied and recommended NSAID for this indication 9

Treatment Guidelines

• The American College of Obstetricians and Gynecologists (ACOG) is not mentioned in this article, however, the general guideline is to consider NSAIDs as an adjunct treatment or for patients refusing hormonal options, with limited efficacy, and to re-evaluate treatment effectiveness at 3-6 months 9

Management of Menorrhagia with Coagulation Disorders

First-Line Medical Management

• The Centers for Disease Control and Prevention recommends screening for bleeding disorders, particularly in adolescents or women with severe thrombocytopenia, as part of the initial assessment for menorrhagia 10
• The American College of Obstetricians and Gynecologists suggests that the levonorgestrel-releasing intrauterine system (LNG-IUS) is particularly beneficial in women with severe thrombocytopenia, as it can effectively treat menorrhagia even in this high-risk population 11
• The Centers for Disease Control and Prevention recommends LNG-IUS as the gold standard for first-line medical management of menorrhagia when contraception is desired or acceptable, with efficacy comparable to endometrial ablation or hysterectomy 10, 11
• Combined oral contraceptives are an effective alternative for first-line medical management of menorrhagia, regularizing cycles and significantly reducing bleeding compared to NSAIDs, antifibrinolytics, or oral progestins 12

Imaging and Endometrial Evaluation in Acute Menorrhagia

Imaging Modalities

• Transvaginal ultrasound is recommended as the first‑line imaging study to identify the most common structural causes of heavy menstrual bleeding—such as uterine fibroids, endometrial polyps, or adenomyosis—in women presenting with acute menorrhagia. 13
• Transvaginal ultrasound may be inadequate for full endometrial visualization when large fibroids, extensive adenomyosis, or patient body habitus limit acoustic windows. 13
• Magnetic resonance imaging (MRI) with diffusion‑weighted sequences improves the sensitivity and specificity for detecting uterine pathology, particularly endometrial carcinoma, when ultrasound findings are inconclusive. 13
• Performing MRI before uterine artery embolization provides a detailed vascular roadmap that can facilitate procedural planning and success. 13

Endometrial Sampling Indications

• Endometrial biopsy is advised for premenopausal women who possess risk factors for endometrial hyperplasia or cancer—such as obesity, diabetes mellitus, polycystic ovary syndrome, or exposure to unopposed estrogen. 13
• Biopsy should also be performed when ultrasound reveals a thickened endometrium (greater than 4 mm) in a premenopausal woman with abnormal uterine bleeding. 13